SOLTI-1805 TOT-HER3 trial: A window-of-opportunity trial of patritumab deruxtecan (HER3-DXd) in patients with treatment-naive, early breast cancer

被引：2

作者：

Oliveira, M. ^{[1
]}

Cejalvo Andujar, J. M. ^{[2
]}

Margeli Vila, M. ^{[3
]}

Tolosa Ortega, P. ^{[4
]}

Martinez Saez, O. ^{[5
]}

Salvador Bofill, F. J. ^{[6
]}

Cruz Jurado, J. ^{[7
]}

Barrera, A. M. Luna ^{[8
]}

Arumi De Dios, M. A. ^{[9
]}

Vidal Losada, M. J. ^{[10
]}

Guerra, J. A. ^{[11
]}

Pernas Simon, S. ^{[12
]}

Villacampa Javierre, G. ^{[13
]}

Gonzalez-Farre, B. ^{[14
]}

Sanfeliu Torres, E. ^{[14
]}

Santhanagopal, A. ^{[15
]}

Falato, C. ^{[16
]}

Ferrero Cafiero, J. M. ^{[17
]}

Pascual, T. ^{[17
]}

Prat, A. ^{[18
]}

机构：

[1] Vall Hebron Univ Hosp, Med Oncol Dept, SOLTI, Barcelona, Spain

[2] Hosp Clin Univ Valencia, Dept Med Oncol, SOLTI, Valencia, Spain

[3] Hosp Badalona Germans Trias & Pujol, ICO Inst Catala Oncol Badalona, Med Oncol Dept, SOLTI, Badalona, Spain

[4] Hosp Univ 12 Octubre, SOLTI, Oncol Dept, Valencia, Spain

[5] Hosp Clin Barcelona, SOLTI, Dept Med Oncol, Barcelona, Spain

[6] Hosp Univ Virgen Valme, Med Oncol Dept, Seville, Spain

[7] Hosp Univ Canarias, Med Oncol Dept, Santa Cruz De Tenerife, Canary Islands, Spain

[8] Hosp Clin Univ San Carlos, Med Oncol Dept, Madrid, Spain

[9] Univ Barcelona, Fac Med, Med Oncol Dept, Barcelona, Spain

[10] Hosp Clin Barcelona, SOLTI, Med Oncol Dept, Barcelona, Spain

[11] Hosp Univ Fuenlabrada, Med Oncol Dept, Fuenlabrada, Spain

[12] Hosp Duran i Reynals, Med Oncol Breast Unit, SOLTI, ICO Inst Catala Oncol Hosp, Lhospitalet De Llobregat, Spain

[13] Vall Hebron Inst Oncol VHIO, Cellex Ctr, Stat Dept, SOLTI, Barcelona, Spain

[14] Hosp Clin Barcelona, Pathol, Barcelona, Spain

[15] Daiichi Sankyo Inc, Res & Dev, Basking Ridge, NJ USA

[16] IDIBAPS August Pi i Sunyer Biomed Res Inst, Translat Genom & Targeted Therapies, Barcelona, Spain

[17] SOLTI HQ, Clin Res Dept, Barcelona, Spain

[18] Hosp Clin Barcelona, IDIBAPS, SOLTI, Dept Med Oncol, Barcelona, Spain

来源：

ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期

关键词：

D O I：

10.1016/j.annonc.2022.07.237

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

202TiP

引用

页码：S628 / S628

页数：1

共 50 条

[21] SOLTI-1802 ONAWA trial: A window of opportunity trial of onapristone (ONA) in postmenopausal women with estrogen and progesterone receptor-positive/HER2-negative (ER+/PgR+/HER2-) early breast cancer (EBC)
Bellet, M.
Morales Murillo, S.
Gasol Cudos, A.
Amillano, K.
Chic, N.
Gonzalez-Farre, X.
Villagrasa, P.
Ferrero-Cafiero, J. M.
Pascual, T.
Prat, A.
Lange, C.
Saura Manich, C.
ANNALS OF ONCOLOGY, 2021, 32 : S36 - S36
[22] Elacestrant in postmenopausal women with estrogen receptor positive and HER2-negative early breast cancer: primary efficacy and safety analysis of the preoperative, window of opportunity SOLTI-1905-ELIPSE trial
Vidal, Maria
Pascual, Tomas
Falato, Claudette
Sanchez-Bayona, Rodrigo
Munoz, Montserrat
Cerbrecos, Isaac
Gonzalez-Farre, Xavier
Cortadellas, Tomas
Margeli, Mireia
Luna, Miguel Angel
Siso, Christian
Amillano, Kepa
Galvan, Patricia
Salvador, Fernando
Espinosa, Alejandra
Pare, Laia
Sanfeliu, Esther
Prat, Aleix
Ezquerra, Meritxell Bellet
CANCER RESEARCH, 2023, 83 (05)
[23] A phase 2 randomized pre-operative,window of opportunity trial investigating the effect of elacestrant with/without triptorelin in premenopausal patients with HR+/HER2-breast cancer-SOLTI2104-PremiERe trial
Bellet-Ezquerra, Meritxell
Hernando, Cristina
Tolosa, Pablo
Vidal, Maria
Fernandez, Yolanda
Gonzalez-Santiago, Santiago
Sanchez, Pilar
De La Cruz, Susana
Ortega, Vanesa
Gonzalez-Farre, Xavier
Bergamino, Milana
Espinosa, Alejandra
Pascual, Tomas
CANCER RESEARCH, 2024, 84 (09)
[24] HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy
Yu, Helena A.
Goto, Yasushi
Hayashi, Hidetoshi
Felip, Enriqueta
Chih-Hsin Yang, James
Reck, Martin
Yoh, Kiyotaka
Lee, Se-Hoon
Paz-Ares, Luis
Besse, Benjamin
Bironzo, Paolo
Kim, Dong-Wan
Johnson, Melissa L.
Wu, Yi-Long
John, Thomas
Kao, Steven
Kozuki, Toshiyuki
Massarelli, Erminia
Patel, Jyoti
Smit, Egbert
Reckamp, Karen L.
Dong, Qian
Shrestha, Pomy
Fan, Pang-Dian
Patel, Parul
Sporchia, Andrea
Sternberg, David W.
Sellami, Dalila
Janne, Pasi A.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (35) : 5363 - +
[25] TROPION-Breast04: A phase 3 study of neoadjuvant datopotamab deruxtecan (Dato-DXd) plus durvalumab followed by adjuvant durvalumab vs the standard of care in treatment-naive early-stage triple negative or HR-low/HER2-breast cancer
McArthur, Heather
Tolaney, Sara
Loibl, Sibylle
Dent, Rebecca
Schmid, Peter
Asselah, Jamil
Song, Erwei
Niikura, Naoki
CANCER RESEARCH, 2024, 84 (09)
[26] Phase 1b/2 trial of the HER3 inhibitor patritumab (U3-1287) in combination with trastuzumab plus paclitaxel in newly-diagnosed patients with HER2+metastatic breast cancer (MBC)
Carraro, S.
Campos, D.
Copigneaux, C.
Saintilien, C.
Beckman, R. A.
Korbenfeld, E.
Coppola, M. P.
Halabe, K.
Cazap, E.
CANCER RESEARCH, 2013, 73
[27] A window-of-opportunity (WOO) trial of giredestrant plus /- LHRHa vs anastrozole plus LHRHa in premenopausal women with ER+/HER2-early breast cancer (EBC; IBCSG 67-22; PREcoopERA)
Munzone, Elisabetta
Shi, Ruichao
Loi, Sherene
Colleoni, Marco
Viale, Giuseppe
Bjelic-Radisic, Vesna
Perello, Antonia
Karlsson, Per
Madaras, Balazs
Connolly, Roisin M.
Ribeiro, Joana M.
Roschitzki-Voser, Heidi
Kammler, Roswitha
Ruepp, Barbara
Regan, Meredith M.
Dubsky, Peter Christian
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[28] A phase 3, open-label trial of neoadjuvant trastuzumab deruxtecan (T-DXd) monotherapy or T-DXd followed by THP compared with ddAC-THP in patients with high-risk HER2-positive early-stage breast cancer (DESTINY-Breast11)
Harbeck, Nadia
Boileau, Jean-Francois
Modi, Shanu
Kelly, Catherine M.
Ohno, Shinji
Wu, Jiong
Brekenridge, Mark
Herbolsheimer, Pia
Yu, Tinghui
Pusztai, Lajos
CANCER RESEARCH, 2022, 82 (04)
[29] Rivaroxaban compared to no treatment in ER-negative stage I–III early breast cancer patients (the TIP Trial): study protocol for a phase II preoperative window-of-opportunity study design randomised controlled trial
John Castle
Emma Blower
Nigel J. Bundred
James R. Harvey
Jecko Thachil
Andrea Marshall
Karina Cox
Silvia Cicconi
Chris Holcombe
Carlos Palmieri
Cliona C. Kirwan
Trials, 21
[30] Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, 3 trial
Andre, Fabrice
Park, Yeon Hee
Kim, Sung-Bae
Takano, Toshimi
Im, Seock-Ah
Borges, Giuliano
Lima, Joao Paulo
Aksoy, Sercan
Gavila Gregori, Joaquin
De Laurentiis, Michelino
Bianchini, Giampaolo
Roylance, Rebecca
Miyoshi, Yasuo
Armstrong, Anne
Sinha, Rajni
Ruiz Borrego, Manuel
Lim, Elgene
Ettl, Johannes
Yerushalmi, Rinat
Zagouri, Flora
Duhoux, Francois P.
Fehm, Tanja
Gambhire, Dhiraj
Cathcart, Jillian
Wu, Cai
Chu, Changan
Egorov, Anton
Krop, Ian
LANCET, 2023, 401 (10390): : 1773 - 1785

← 1 2 3 4 5 →